Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Neoplasm Metastasis × Imlunestrant × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasm Metastasis 1 Breast Neoplasms 1

Interventions

trastuzumab deruxtecan 3 eribulin 2 Gemcitabine 2 Capecitabine 2 telisotuzumab vedotin 1 pembrolizumab 1 osimertinib 1 olaparib 1 margetuximab 1 exemestane 1 entrectinib 1 encorafenib 1 dacomitinib 1 capmatinib 1 binimetinib 1 adagrasib 1 abemaciclib 1 Vinorelbine 1 Vemurafenib 1 Trastuzumab 1 Pemetrexed 1 Paclitaxel 1 Imlunestrant 1 Gefitinib 1 Fulvestrant 1 Cisplatin 1 Cetuximab 1 Carboplatin 1 Afatinib 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04975308 2025-07-11

EMBER-3

Eli Lilly and Company

Phase 3 Active not recruiting

874 enrolled 29 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡